Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma

References

• KyleRATherneauTMRajkumarSVA long-term study of prognosis in monoclonal gammopathy of undetermined significanceN Engl J Med2002346856456911856795
   PubMed Web of Science ®Google Scholar
• PalumboAAndersonKMultiple myelomaN Engl J Med2011364111046106021410373
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• FayersPMPalumboAHulinCThalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trialsBlood201111851239124721670471
   PubMed Web of Science ®Google Scholar
• Sanz-RodríguezFRuiz-VelascoNPascual-SalcedoDCharacterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1Br J Haematol199910782583410606891
   PubMed Web of Science ®Google Scholar
• CoppolaATufanoADi CapuaMFranchiniMBleeding and thrombosis in multiple myeloma and related plasma cell disordersSemin Thromb Hemostas2011378929945
   Web of Science ®Google Scholar
• SallahSWanJYNguyenNPVenous thrombosis in patients with solid tumors: determination of frequency and characteristicsThromb Haemost200287457557912008937
   PubMed Web of Science ®Google Scholar
• BlomJWDoggenCJOsantoSMalignancies, prothrombotic mutations, and the risk of venous thrombosisJAMA2005293671572215701913
   PubMed Web of Science ®Google Scholar
• KhoranaAAConnollyGCAssessing risk of venous thromboembolism in the patient with cancerJ Clin Oncol200927294839484719720906
   PubMed Web of Science ®Google Scholar
• BlomJWVanderschootJPOostindiërMJIncidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage studyJ Thromb Haemost20064352953516460435
   PubMed Web of Science ®Google Scholar
• SimanekRVormittagRAyCHigh platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)J Thromb Haemost20108111412019889150
   PubMed Web of Science ®Google Scholar
• MackmanNNew insights into the mechanisms of venous thrombosisJ Clin Invest201212272331233622751108
   PubMed Web of Science ®Google Scholar
• FleitasTMartínez-SalesVVilaVCirculating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancerPLoS One2012710e4736523077602
   PubMed Web of Science ®Google Scholar
• NaumnikWNilklińskaWOssolińskaMChyczewskaESerum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapyFolia Histochem Cytobiol200947470370920430742
   PubMed Web of Science ®Google Scholar
• SuCYLiuYPYangCJPlasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancerPLoS One2015107e013341126230665
   PubMed Web of Science ®Google Scholar
• DucrosEMirshahiSSFaussatAMSoluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignanciesCancer Med20121226126723342274
   PubMed Web of Science ®Google Scholar
• DriAPPolitouMGialerakiADecreased incidence of EPCR 4678G/C SNP in multiple myeloma patients with thrombosisThromb Res2013132340040123993723
   PubMed Web of Science ®Google Scholar
• AuwerdaJJYuanaYOsantoSMicroparticle-associated tissue factor activity and venous thrombosis in multiple myelomaThromb Haemost20111051142021057704
   PubMed Web of Science ®Google Scholar
• BenameurTChappardDFioleauEPlasma cells release membrane microparticles in a mouse model of multiple myelomaMicron201354557581
   Web of Science ®Google Scholar
• KrishnanSRLukFBrownRDIsolation of Human CD138(+) microparticles from the plasma of patients with multiple myelomaNeoplasia2016181253226806349
   PubMed Web of Science ®Google Scholar
• RoyMLiangLXiaoXLycorine downregulates HMGB1 to inhibit autophagy and enhances Bortezomib activity in multiple myelomaTheronostics201661222092224
   PubMed Web of Science ®Google Scholar
• ChongBHLeeSHManagement of thromboembolism in hematologic malignanciesSemin Thromb Hemost200733443544817525901
   PubMed Web of Science ®Google Scholar
• FranchiniMDario Di MinnoMHCoppolaADisseminated intravascular coagulation in hematologic malignanciesSemin Thromb Hemost201036438840320614391
   PubMed Web of Science ®Google Scholar
• ValsamiSRufWLeikaufMSImmunomodulatory drugs increase endothelial tissue factor expression in vitroThromb Res2011127326427121159364
   PubMed Web of Science ®Google Scholar
• RosovskyRHongFToccoDEndothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational studyBr J Haematol2013160335135823240658
   PubMed Web of Science ®Google Scholar
• GaoYMaGLiuSThalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitroThromb Res201513561154115925840743
   PubMed Web of Science ®Google Scholar
• RajkumarSVKyleRATherneauTMSerum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood2005106381281715855274
   PubMed Web of Science ®Google Scholar
• DaviesFEWuPJennerMSrikanthMSasoRMorganGJThe combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasoneHaematologica20079281149115017650451
   PubMed Web of Science ®Google Scholar
• BrownSHinsleySBallesterosMThe MUK five protocol: a phase II randomised, controlled, parallel group, multicentre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaBMC Hematol2016161427190631
   PubMedGoogle Scholar
• RajkumarSVJacobusSCallanderNSLenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialLancet Oncol2010111293719853510
   PubMed Web of Science ®Google Scholar
• ReeceDEMasih-KhanEAtenafuEGPhase I–II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myelomaBr J Haematol20151681465425146584
   PubMed Web of Science ®Google Scholar
• OsumiKOzekiYSaitoSDevelopment and assessment of enzyme immunoassay for platelet-derived microparticlesThromb Haemost200185232633011246556
   PubMed Web of Science ®Google Scholar
• NomuraSUehataSSaitoSOsumiKOzekiYKimuraYEnzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndromeThromb Haemost200389350651212624635
   PubMed Web of Science ®Google Scholar
• EbyCPathogenesis and management of bleeding and thrombosis in plasma cell dyscrasiasBr J Haematol2009145215116319210509
   PubMed Web of Science ®Google Scholar
• LeebeekFWKruipMJSonnevelsPRisk and management of thrombosis in multiple myelomaThromb Res2012129Suppl 1S88S9222682142
   PubMed Web of Science ®Google Scholar
• WangXLiYYanXEfficacy and safety of novel agent-based therapies for multiple myeloma: a meta-analysisBioMed Res Int20162016684890226949704
   PubMed Web of Science ®Google Scholar
• Martinez-LopezJBladeJMateosMVLong-term prognostic significance of response in multiple myeloma after stem cell transplantationBlood2011118352953421482708
   PubMed Web of Science ®Google Scholar
• PalumboAHajekRDelforgeMContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med2012366191759176922571200
   PubMed Web of Science ®Google Scholar
• MateosMVHernándezMTGiraldoPLenalidomide plus dexamethasone for high-risk smoldering multiple myelomaN Engl J Med2013369543844723902483
   PubMed Web of Science ®Google Scholar
• PetrucciMTLeviABringhenSBortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 studyCancer2013119597197723096113
   PubMed Web of Science ®Google Scholar
• TouzeauCMoreauPDumontetCMonoclonal antibody therapy in multiple myelomaLeukemia2017311927389053
   PubMed Web of Science ®Google Scholar
• CastellinoFJPloplisVAThe protein C pathway and pathologic processesJ Thromb Haemost20097Suppl 114014519630787
   PubMed Web of Science ®Google Scholar
• Van Hylckama VliegAMontesRRosendaalFRHermidaJAutoantibodies against endothelial protein C receptor and the risk of a first deep vein thrombosisJ Thromb Haemost2007571449145417439632
   PubMed Web of Science ®Google Scholar
• FukudomeKKurosawaSStearns-KurosawaDJHeXRezaieAREsmonCTThe endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptorJ Biol Chem19962712917491174988663475
   PubMed Web of Science ®Google Scholar
• AlthawadiHAlfarsiHBesbesSThe endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptorOncol Lep2015342603609
   Web of Science ®Google Scholar
• Cesarman-MausGBraggioEFonsecaRThrombosis in multiple myeloma (MM)Hematology2012171S177S18022507814
   PubMed Web of Science ®Google Scholar
• PalumboARajkumarSVDimopoulosMAPrevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia200822241442318094721
   PubMed Web of Science ®Google Scholar
• CarrierMLe GalGTayJWuCLeeAYRates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysisJ Thromb Haemost20119465366621255254
   PubMed Web of Science ®Google Scholar
• QuDWangYEsmonNLEsmonCTRegulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17J Thromb Haemost20075239540217155946
   PubMed Web of Science ®Google Scholar
• MossMLLambertMHShedding of membrane proteins by ADAM family proteasesEssays Biochem20023814115312463167
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAAChittaKErsingNBiological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour responseBr J Haematol2011155445746722010965
   PubMed Web of Science ®Google Scholar
• MaigaSGomez-BougiePBonnaudSParadoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myelomaBr J Cancer201310891801180623632478
   PubMed Web of Science ®Google Scholar
• MullerGWChenRHuangSYAmino-substituted thalidomide analogs: potent inhibitors of TNF-alpha productionBioorg Med Chem Lett19999111625163010386948
   PubMed Web of Science ®Google Scholar